Loading
A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy is a phase 3 interventional study registered as NCT03767244 by Janssen Research & Development, LLC, with 2517 participants enrolled, started 2019-06-11 and due to reach its primary completion in 2026-12-01. Interventions recorded: Apalutamide, Androgen Deprivation Therapy (ADT) and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/